South Africa Newborn Screening Software Market Size & Outlook, 2026-2034
South Africa Newborn Screening Software Market Insights
- Based on Reed Intelligence findings, the South Africa Newborn Screening Software Market reached USD 14.88 Million in 2025 and is estimated to attain USD 30.63 Million by 2034.
- From 2026 to 2034, the South Africa market is expected to grow at a steady CAGR of 8.38%.
- Within the By Product category, Instruments dominated in 2025 in terms of market size contribution.
- Over the forecast period, Reagents is forecasted to deliver the fastest growth, positioning it as the most lucrative By Product segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- South Africa contributed 1.06% to the global Newborn Screening Software Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Newborn Screening Software Market.
- In Middle East and Africa, United Arab Emirates is projected to capture the leading share of market size by 2034.
- Among Middle East and Africa markets, South Africa is expected to post the fastest growth, reaching USD 30.7 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 14.88 Million |
| Market Size In 2034 | USD 30.63 Million |
| Largest segment | Instruments |
| Units | Revenue in USD Million |
| CAGR | 8.38% (2026-2034) |
| Segmnetation Covered | |
| By Product |
|
| By Technology |
|
| By Test Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South Africa Newborn Screening Software Market By Product 2026-2034 (USD Million)
| By Product | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments | XX.x | XX.x | XX.x | 8.33 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reagents | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Africa Newborn Screening Software Market By Technology 2026-2034 (USD Million)
| By Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tandem Mass Spectrometry | XX.x | XX.x | XX.x | 4.5 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pulse Oximetry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enzyme Based Assay | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| DNA Assay | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Electrophoresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Africa Newborn Screening Software Market By Test Type 2026-2034 (USD Million)
| By Test Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry Blood Spot Test | XX.x | XX.x | XX.x | 6.84 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| CCHD | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hearing Screen | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.